BCRX

In the past six months, BioCryst Pharmaceuticals' stock (BCRX) has experienced several notable events, including the report of Q1 2026 financial results showing a GAAP operating loss of $701.6 million, primarily due to a significant non-cash charge. ORLADEYO net revenue for Q1 2026 was $148.3 million, an 11% year-over-year increase, and total revenue reached $156.4 million. The company reaffirmed its full-year 2026 guidance for global ORLADEYO net revenue of $625 million to $645 million and total revenue of $635 million to $660 million. A licensing agreement in May 2026 with an Irish affiliate of Neopharmed Gentili for European commercial rights to navenibart included a $70 million upfront payment and potential milestones up to $275 million. In February 2026, BioCryst reported strong Q4 2025 earnings, with EPS soaring to $1.12 and revenue tripling to approximately $406.6 million. The company also finalized the $700 million acquisition of Astria Therapeutics in January 2026. Analyst ratings have seen some adjustments, and the stock's 52-week trading range has been between $6.00 and $11.31.